

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Zhaoke Ophthalmology Limited**  
**兆科眼科有限公司**

*(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)*  
**(Stock Code: 6622)**

**(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR;  
(2) CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE;  
AND  
(3) UPDATES ON NON-COMPLIANCE WITH THE LISTING RULES**

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE  
IN COMPOSITION OF THE AUDIT COMMITTEE**

Reference is made to the announcement of Zhaoke Ophthalmology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated April 11, 2022 in relation to, among other matters, the resignation of an independent non-executive director and non-compliance with the Rules Governing the Listing of the Securities on the Stock Exchange (“**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of the Company is pleased to announce that Mr. Liew Fui Kiang (“**Mr. Liew**”) has been appointed as an independent non-executive Director and a member of the audit committee of the Board with effect from June 6, 2022.

Mr. Liew, aged 55, is currently an independent non-executive director of (i) Shandong Gold Mining Co., Ltd., a company dually listed on the The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 1787) and Shanghai Stock Exchange (stock code: 600547); (ii) China Apex Group Limited, a company listed on the Stock Exchange (stock code: 2011); (iii) Zhengye International Holdings Company Limited, a company listed on the Stock Exchange (stock code: 3363); and (iv) Zhongchang International Holdings Group Limited, a company listed on the Stock Exchange (stock code: 859).

Mr. Liew served as (i) the chairman of the board of directors and an executive director of PacRay International Holdings Limited, a company listed on the Stock Exchange (stock code: 1010) from 2017 to 2019; (ii) a non-executive director of Amber Hill Financial Holdings Limited (a company listed on the Stock Exchange with stock code: 33) in December 2019; and (iii) an independent non-executive director of Baoshan Iron & Steel Company Limited\* (寶

山鋼鐵股份有限公司), a company listed on Shanghai Stock Exchange (stock code: 600019), a Fortune Global 500 company, from 2000 to 2006. The Board believes that Mr. Liew's extensive experience in corporate governance and strategic decision-making with directorships in public companies qualifies him to serve on the Board.

Mr. Liew obtained his bachelor's degree in laws as a Tetley & Lupton scholar from the University of Leeds in the United Kingdom in 1989 and his master's degree in business administration from the Hull University Business School of the United Kingdom in 1996. He is a fellow of the Hong Kong Institute of Directors, a solicitor of England and Wales, and a solicitor of Hong Kong.

Save as disclosed above, Mr. Liew does not hold any other positions in the Company or any members of the Group nor does he have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (within the meaning of the Listing Rules of the Company. As at the date of this announcement, Mr. Liew does not have, and is not deemed to have, any other interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement and as at the date hereof, Mr. Liew does not hold any other directorships in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Mr. Liew will enter into a letter of appointment with the Company as an independent non-executive Director for an initial term of three year commencing from June 6, 2022 subject to termination by either party with three month's written notice. Mr. Liew will hold office until the first general meeting of the Company after his appointment and shall be eligible for re-election in accordance with the articles of association of the Company. Mr. Liew is entitled to receive a Director's fee of HK\$300,000 per annum which is determined with reference to the prevailing market conditions, the Company's performance, his time, effort and expertise to be exercised on the Group's affairs and the Company's remuneration policy.

Save as disclosed herein, to the best of knowledge, information and belief of the Directors having made all reasonable enquiries, there was no other matters with respect to the appointment of Mr. Liew that needs to be brought to the attention of the Shareholders and there was no information relating to Mr. Liew that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules as at the date of this announcement.

## **UPDATES ON NON-COMPLIANCE WITH THE LISTING RULES**

Following the appointments of Mr. Liew, the Company has fully complied with the requirements as set out in Rules 3.10A, 3.10(1) and 3.21 of the Listing Rules.

The Board would like to express its warmest welcome to Mr. Liew for his new role in the Company.

By order of the Board  
**Zhaoke Ophthalmology Limited**  
**Dr. Li Xiaoyi**  
*Chairman*

Hong Kong, June 6, 2022

*As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee, Ms. Tiantian Zhang, Ms. Cai Li and Mr. Chen Yu as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.*

*\* For identification purpose only*